On 12-15 February, phenox celebrated its 7th international Kickoff meeting in Athens. The company had the pleasure to welcome numerous new distribution partners due to an increased geographical footprint.
On Dec, 9th, representatives of the two contract partners phenox and Wallaby Medical met in Shanghai to finalize a strategic partnership. The cooperation focuses on the sale of Wallaby Medical’s Avenir Embolic Coil System for the treatment of brain aneurysms. The system is approved in the CE and FDA markets and is already marketed by phenox in the USA.
phenox is pleased to announce that it has signed an exclusive distribution agreement with Wallaby Medical Inc. for commercialization of The Avenir™ Detachable Coil System in the U.S. and EU markets. The intended use for the Avenir Coil System is for endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The Avenir Coil System is also intended for arterial and venous embolization in the peripheral vasculature.
“The Avenir Coil is highly complementary to our existing portfolio of neurovascular technologies, and we are looking forward to our commercial partnership with Wallaby Medical” said James Lago, CEO of phenox Inc. and General Manager, International of phenox GmbH.
The Avenir Coil System offers a full line of coils including exceptional stable framing coils, extra volume filling coils and ultra-soft finishing coils. Avenir has a streamlined and intuitive, integrated mechanical detachment mechanism with no handle or external energy source required.
Founded in 2005, phenox is a privately held company that develops and manufactures innovative treatment options for both hemorrhagic and acute ischemic stroke. phenox has operations in Germany, Ireland, and the United States.
About Wallaby Medical
Wallaby Medical, Inc. is a private company located in Laguna Hills, California that focusses on developing products for treating hemorrhagic and ischemic stroke.
Named the queen of Belgrade by EBSA.tv, Diana Stateczny became Europe’s 2019 snooker champion. Her 24 years of training at the table with a decade dedicated to snooker paid off.
Her victory is impressive. She doesn’t train like the others, she works full time on top of training. To a certain extent, she admits her work is part of her training and it contributed to make her the person she is today: down to earth, focused and dynamic.
“When I go play snooker after a working day behind the microscope, I have learned how to stay present, focused, and work on my endurance. My job also helped me become a more flexible person. When I went to Ireland for a few weeks, I did not train at all. On my return, I realized how grateful I was to play snooker again and this break brought me a lot.”
Discrete, calm yet ambitious, Diana is a confident women who constantly seeks to grow both at work and in snooker. When she works, she is concentrated, disciplined and precise, the same way she plays.
“phenox is proud to have Diana on the team and we are thrilled about her great victory”, says Dr.-Ing. Hermann Monstadt, managing partner at phenox.
The „AntiThromb“ project is announced to be the winner of the KMU-NetC competition of the Federal Ministry of Education and Researsch and therefore receives an enormous funding out of federal resources. The goal of the phenox project is to develop a path-breaking coating, which imitates the natural vessel wall, to be used on implants for the treatment of cerebral aneurysms. The use of such a coating it would make it possible to reduce lifelong medication which still is the current standard.Such a medication is necessary to prevent the formation of a thrombus caused by the use of implants in the cerebral artery and therefore presents the standardized procedure. „For patients where medications do not take effect or are not favorable for other clinical reasons, coated implants could be a promising alternative.” says phenox CEO and managing partner Dr.-Ing. Hermann Monstadt. The challenges of developing such a technology consist in the processing of innovative combinations of raw material, the specialized coating technology as well as the production of the filigree implant structures. Through surface coating the implant is made almost “invisible” to the human immune system to prevent any kind of thromboembolic reactions.The overall volume of the „AntiThromb“ funding project comprises of 2.1 million Euro and is planned to be ongoing for 24 months. Apart of phenox GmbH, being in the production of medical products for the treatment of neurovascular strokes for more than 10 years, other Bochum located companies take part as well. Those are femtos GmbH, a start-up company specialized on miniaturized laser polishing procedure, the department for engineering of Ruhr-University Bochum, Knappschaftschaftskrankenhaus Bochum Hospital as well as the Leibniz Institute of Analytical Sciences –ISAS – e.V. Dortmund and OxProtext GmbH located in Münster. The project is coordinated by NanoMikroWerkstoffPhotonik.NRW Cluster.The support measure „„KMU-NetC“ of the 10-point-programm „priority for the middle class“ the Federal Ministry for Education and Science supports small and medium sized companies in regional networks and clusters. These companies are especially challenged by continuously renewing their processes, products, services and business models in terms of opening up new market potentials. A helpful factor is the association with other companies, universities or research institutes, who have already been successful at developing similar innovation strategies. Experiences and competences are being shared which alleviates and accelerates innovation in the mid-sized sector.